AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer
Obtaining patent approval for a therapeutic application of masitinib enhances AB Science's potential to protect its intellectual property, potentially...
Read Full Article →